5-Fluorouracil: a narrative review on the role of regulatory mechanisms in driving resistance to this chemotherapeutic agent
5-fluorouracil (5-FU) is among the mostly administrated chemotherapeutic agents for a wide
variety of neoplasms. Non-coding RNAs have a central impact on the determination of the …
variety of neoplasms. Non-coding RNAs have a central impact on the determination of the …
[HTML][HTML] MicroRNAs in the prognosis and therapy of colorectal cancer: From bench to bedside
KKW To, CWS Tong, M Wu… - World journal of …, 2018 - ncbi.nlm.nih.gov
MicroRNAs (miRNAs) are small, single-stranded, noncoding RNAs that can post-
transcriptionally regulate the expression of various oncogenes and tumor suppressor genes …
transcriptionally regulate the expression of various oncogenes and tumor suppressor genes …
Long non-coding RNAs in anti-cancer drug resistance
Q Chen, C Wei, Z Wang, M Sun - Oncotarget, 2016 - pmc.ncbi.nlm.nih.gov
Chemotherapy is one of the basic treatments for cancers; however, drug resistance is mainly
responsible for the failure of clinical treatment. The mechanism of drug resistance is …
responsible for the failure of clinical treatment. The mechanism of drug resistance is …
Perspectives of using microRNA-loaded nanocarriers for epigenetic reprogramming of drug resistant colorectal cancers
OA Sukocheva, J Liu, ME Neganova… - Seminars in Cancer …, 2022 - Elsevier
Epigenetic regulation by microRNAs (miRs) demonstrated a promising therapeutic potential
of these molecules to regulate genetic activity in different cancers, including colorectal …
of these molecules to regulate genetic activity in different cancers, including colorectal …
The network of non-coding RNAs in cancer drug resistance
F Corrà, C Agnoletto, L Minotti, F Baldassari… - Frontiers in …, 2018 - frontiersin.org
Non-coding RNAs (ncRNAs) have been implicated in most cellular functions. The disruption
of their function through somatic mutations, genomic imprinting, transcriptional and post …
of their function through somatic mutations, genomic imprinting, transcriptional and post …
Influence of microRNAs and long non-coding RNAs in cancer chemoresistance
D Ayers, J Vandesompele - Genes, 2017 - mdpi.com
Innate and acquired chemoresistance exhibited by most tumours exposed to conventional
chemotherapeutic agents account for the majority of relapse cases in cancer patients. Such …
chemotherapeutic agents account for the majority of relapse cases in cancer patients. Such …
Long non-coding RNA LINC00152 promotes cell proliferation, metastasis, and confers 5-FU resistance in colorectal cancer by inhibiting miR-139-5p
Z Bian, J Zhang, M Li, Y Feng, S Yao, M Song, X Qi… - Oncogenesis, 2017 - nature.com
Long intergenic non-coding RNA 152 (LINC00152) is a recently identified tumor-promoting
long non-coding RNA. However, the biological functions of LINC00152 in colorectal cancer …
long non-coding RNA. However, the biological functions of LINC00152 in colorectal cancer …
Ensemble of kernel ridge regression-based small molecule–miRNA association prediction in human disease
MicroRNAs (miRNAs) play crucial roles in human disease and can be targeted by small
molecule (SM) drugs according to numerous studies, which shows that identifying SM …
molecule (SM) drugs according to numerous studies, which shows that identifying SM …
[HTML][HTML] Resistance to cancer chemotherapeutic drugs is determined by pivotal microRNA regulators
M Geretto, A Pulliero, C Rosano… - American journal of …, 2017 - ncbi.nlm.nih.gov
Chemo-resistance, which is the main obstacle in cancer therapy, is caused by the onset of
drug-resistant cells in the heterogeneous cell population in cancer tissues. MicroRNAs …
drug-resistant cells in the heterogeneous cell population in cancer tissues. MicroRNAs …
MicroRNAs and colorectal cancer chemoresistance: New solution for old problem
Background Colorectal cancer (CRC) is one of the most common gastrointestinal
malignancies with a significant mortality rate. Despite the great advances in cancer …
malignancies with a significant mortality rate. Despite the great advances in cancer …